Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target

A major rate-limiting step in developing more effective immunotherapies for GBM is our inadequate understanding of the cellular complexity and the molecular heterogeneity of immune infiltrates in gliomas. Here, we report an integrated analysis of 201,986 human glioma, immune, and other stromal cells at the single cell level. In doing so, we discover extensive spatial and molecular heterogeneity in immune infiltrates. We identify molecular signatures for nine distinct myeloid cell subtypes, of which five are independent prognostic indicators of glioma patient survival. Furthermore, we identify S100A4 as a regulator of immune suppressive T and myeloid cells in GBM and demonstrate that deleting S100a4 in…

• UD
  U.S. Department of Defense

  Award: W81XWH
• CP
  Cancer Prevention and Research Institute of Texas

  Award: RP180882
• BF
  Broach Foundation for Brain Cancer Research
• NI
  National Institutes of Health

  Awards: P50CA127001, W81XWH
• UO
  University of Texas MD Anderson Cancer Center
• HM
  Houston Methodist Research Institute
• NC
  National Cancer Institute

  Award: P50CA127001
• NI
  National Institute of Neurological Disorders and Stroke

  Award: 1R01NS121405
• UA
  U.S. Army Corps of Engineers

  Awards: W81XWH-14-1-0115, CA191052